Skip to main content
Equibles

GLAXO · GlaxoSmithKline Pharmaceuticals Limited · Financials

Use GLAXO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLAXO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,669.55 INR +14.25 (+0.54%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 4480 Avg daily vol (14 sessions) 12.12K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
38.22B +1.9%
FY2026 Revenue FY2020–FY2026
Net Income
10.36B
FY2026 Net Income FY2020–FY2026
Operating Cash Flow
9.03B -30%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
INR 41.59B 38.22B 37.49B 34.54B 32.52B 32.78B 31.99B 32.24B
INR 643.5M 664.4M 667.9M 696.8M 657.7M 681.9M 792.8M 826.78M
INR 32.6M 27.3M 13.1M 18M 18.1M 20M 35.3M 63.36M
INR 15.55B 14.06B 12.6B 8.16B 8.36B 7.79B 5.51B 3.06B
INR 4.08B 3.7B 3.32B 2.26B 2.29B 3.98B 1.92B 2.13B
INR 5.15B 10.36B 0 5.9B 6.11B 16.95B 3.58B 932M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 40.37B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.